Opioid Use Disorder Market , By Drug Type (Buprenorphine, Methadone, Naltrexone, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Oct 2023

Code : CMI4597

Pages :198

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

Product recall

Global Opioid Use Disorder Market- Drivers

Rising prevalence of opioid use disorder

Rising prevalence of opioid use disorder among the population is expected to drive growth of the the global opioid use disorder market over the forecast period. For instance, in 2020, according to the data published by National Institute on Drug Abuse, an estimated 2.7 Mn people aged 12 or older, in the U.S. had an opioid use disorder (OUD) including 2.3 Mn people with a prescription opioid use disorder.

Growth Drivers:

Rising prevalence of opioid use disorder
Increasing organic growth strategies such as product approval

Increasing organic growth strategies such as product approval

Increasing organic growth strategies such as product approval by regulatory authorities to expand product portfolio of the key market players is expected to drive growth of the global opioid use disorder market over the forecast period. For instance, in April 2020, Amneal Pharmaceuticals, Inc., a pharmaceutical company, announced that it had received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of butrans (buprenorphine) transdermal system, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr. Amneal Pharmaceuticals, Inc. was granted the competitive generic Ttherapy (CGT) designation and 180 days of exclusivity for the 7.5 mcg/hr dose.

Global Opioid Use Disorder Market: Restraint

Product recall: Factors such as product recall and side effects associated with the use of opioids is expected to hamper the growth of the global opioid use disorder market over the forecast period. For instance, on July 14, 2021, according to U.S. Food and Drug Administration (FDA) Enforcement Report, Alvogen, a pharmaceuticals company, recalled a single lot of buprenorphine and naloxone sublingual films due to subpotency. The recall affects buprenorphine and naloxone sublingual film 2 mg/0.5 mg, 30 pouches containing one sublingual film each (NDC 47781-355-11), from lot 36924 (Exp. 6/21).
Counterbalance: The key market players are focusing s on maintaining quality of products to reduced product recall.